Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Estimated 1,024 Patients Took Xocova in First 11 Days: Shionogi
Shionogi’s oral COVID-19 treatment Xocova (ensitrelvir) has been administered to an estimated 1,024 patients in the first 11 days since the start of its distribution in Japan, according to a report released by the company. Between November 24 and December…
To read the full story
Related Article
- Xocova Given to Over 50,000 Patients in 6 Months: Shionogi
June 6, 2023
- No Additional Safety Measures Needed at this Time for Xocova: Panel
May 11, 2023
- Over 40,000 Patients Given Xocova as of April 9: Shionogi
April 18, 2023
- Estimated 37,746 Patients Given Xocova as of March 19: Shionogi
March 29, 2023
- Additional Safety Measures for Xocova “Not Needed at This Time”: MHLW Panel
March 24, 2023
- Serious Side Effect Cases Total 8: Xocova Safety Update
March 13, 2023
- Xocova Taken by Estimated 32,270 Patients as of Feb. 19: Shionogi
February 28, 2023
- MHLW Panel Maintains Caution against Xocova Use in Women Who Might Be Pregnant
February 22, 2023
- Xocova’s Serious Side Effect Cases Total 5: Shionogi
February 13, 2023
- Estimated 11,867 Patients Given Xocova as of Jan. 5: Shionogi
January 16, 2023
- Shionogi Reports 2 Serious Side Effect Cases in Xocova Update
January 6, 2023
- No Add'l Safety Measures for Xocova Needed “at This Time”: MHLW Panel
December 28, 2022
- Estimated 4,640 Patients Took Xocova by Dec. 18: Shionogi
December 27, 2022
BUSINESS
- Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
February 26, 2026
- Nippon Kayaku Aims to Lift New Drug Sales Ratio to 30%, Bolsters Oncology Push
February 25, 2026
- Keio Spinoff Taps Nikon as CDMO, Targets 2027 Start for KP8011 Trial
February 25, 2026
- Astellas, Vir Strike Strategic Deal to Advance PSMA-Targeting TCE
February 25, 2026
- Nippon Shinyaku to Take Over UCB’s Fintepla in Japan from April
February 25, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…